Loading...
XKRX
008930
Market cap1.70bUSD
Dec 05, Last price  
36,950.00KRW
1D
-0.40%
1Q
-5.98%
Jan 2017
-39.53%
Name

Hanmi Science Co Ltd

Chart & Performance

D1W1MN
XKRX:008930 chart
P/E
42.11
P/S
1.95
EPS
877.54
Div Yield, %
0.27%
Shrs. gr., 5y
0.12%
Rev. gr., 5y
9.46%
Revenues
1.28t
+2.85%
531,396,197,000606,802,686,000689,962,982,000641,470,958,00016,812,302,74019,645,989,150219,862,566,010532,604,690,900776,215,271,160665,284,666,050652,324,367,920707,995,356,120816,618,823,610857,383,419,140950,164,817,3401,046,054,210,8301,247,906,379,0601,283,432,296,000
Net income
59.42b
-48.38%
52,997,718,00071,551,234,00050,526,894,0005,977,013,000-14,690,506,00012,479,133,0009,578,328,00021,312,164,080178,520,883,2207,937,683,00030,068,972,51018,019,525,57030,741,649,30022,601,096,23042,941,995,98069,209,578,700115,121,512,76059,421,641,000
CFO
82.99b
+136.04%
-16,175,604,00040,923,068,00060,933,793,00036,493,513,000-7,675,597,550-175,636,290-234,788,3005,245,497,90046,927,261,70076,523,442,300-33,681,816,8402,701,370,43013,024,009,77013,817,514,74013,689,812,1009,451,693,03035,158,260,38082,986,394,000
Dividend
Jun 27, 2024100 KRW/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Hanmi Science Co., Ltd., through its subsidiaries, manufactures and sells pharmaceutical products in Korea and internationally. It develops drugs in the areas of diabetes and anti-cancer. The company also offers drug substances, general medicines, health functional foods, and nutrition and health products and services. In addition, it operates an online pharmacy; and offers pharmaceutical management automation systems. The company was formerly known as Hanmi Holdings Co., Ltd. and changed its name to Hanmi Science Co., Ltd. in March 2012. Hanmi Science Co., Ltd. was founded in 1973 and is based in Seoul, South Korea.
URL
http://www.hanmiscience.co.kr/
IPO date
Jun 20, 1988
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT